Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: Implications in breast cancer cell survival and migration

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Papanastasiou, Anastasios D ^a   Sirinian, Chaido ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; DOXORUBICIN; ISOPROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BREAST TUMOR; CELL MEMBRANE; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE ORDER; GENETICS; HUMAN; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CELL SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; HUMANS; PROTEIN ISOFORMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84865114435     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3234     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
3. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807. 10.1038/nature09091, 20445538.
4. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802. 10.1038/nature09027, 20383121.
5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50. 10.1016/S0092-8674(00)00103-3, 11051546.
6. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J, Paquet M, DeMayo FJ, Lydon JP. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 2009, 328:127-139. 10.1016/j.ydbio.2009.01.019, 19298785.
7. Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006, 26:1002-1013. 10.1128/MCB.26.3.1002-1013.2006, 1347028, 16428453.
8. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107. 10.1038/nature09495, 20881963.
9. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102. 10.1038/nature09387, 3084017, 20881962.
10. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553. 10.1038/nature09707, 3166217, 21326202.
11. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696. 10.1038/nature04524, 16572175.
12. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179. 10.1038/36593, 9367155.
13. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997, 186:2075-2080. 10.1084/jem.186.12.2075, 2199171, 9396779.
14. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323. 10.1038/16852, 9950424.
15. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571. 10.1073/pnas.97.4.1566, 26475, 10677500.
16. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, Penninger JM. Central control of fever and female body temperature by RANKL/RANK. Nature 2009, 462:505-509. 10.1038/nature08596, 19940926.
17. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999, 190:1741-1754. 10.1084/jem.190.12.1741, 2195707, 10601350.
18. Kido S, Inoue D, Hiura K, Javier W, Ito Y, Matsumoto T. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. Bone 2003, 32:621-629. 10.1016/S8756-3282(03)00049-8, 12810169.
19. Cannon JG, Kraj B, Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokine 2011, 53:141-144. 10.1016/j.cyto.2010.11.011, 3021651, 21159522.
20. Ishii J, Kitazawa R, Mori K, McHugh KP, Morii E, Kondo T, Kitazawa S. Lipopolysaccharide suppresses RANK gene expression in macrophages by down-regulating PU.1 and MITF. J Cell Biochem 2008, 105:896-904. 10.1002/jcb.21886, 18759249.
21. Khapli SM, Tomar GB, Barhanpurkar AP, Gupta N, Yogesha SD, Pote ST, Wani MR. Irreversible inhibition of RANK expression as a possible mechanism for IL-3 inhibition of RANKL-induced osteoclastogenesis. Biochem Biophys Res Commun 2010, 399:688-693. 10.1016/j.bbrc.2010.07.143, 20691668.
22. Hakozaki A, Yoda M, Tohmonda T, Furukawa M, Hikata T, Uchikawa S, Takaishi H, Matsumoto M, Chiba K, Horiuchi K, Toyama Y. Receptor activator of NF-kappaB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages. J Immunol 2010, 184:2442-2448. 10.4049/jimmunol.0901188, 20118276.
23. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998, 273:34120-34127. 10.1074/jbc.273.51.34120, 9852070.
24. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001, 107:763-775. 10.1016/S0092-8674(01)00599-2, 11747812.
25. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
26. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476. 10.1038/nature07509, 2593745, 18978772.
27. Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008, 283:14177-14181. 10.1074/jbc.R700052200, 2386928, 18385130.
28. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci USA 2001, 98:1751-1756. 10.1073/pnas.98.4.1751, 29329, 11172023.
29. Papanastasiou AD, Mantagos S, Papanastasiou DA, Zarkadis IK. A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome. Mol Immunol 2010, 47:1629-1634. 10.1016/j.molimm.2010.01.010, 20149460.
30. Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H. Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer 2009, 8:109. 10.1186/1476-4598-8-109, 2789046, 19930708.
31. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 1998, 273:20551-20555. 10.1074/jbc.273.32.20551, 9685412.
32. Kanazawa K, Kudo A. Self-assembled RANK induces osteoclastogenesis ligand-independently. J Bone Miner Res 2005, 20:2053-2060. 10.1359/JBMR.050706, 16234979.
33. Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 2007, 27:1442-1454. 10.1128/MCB.01298-06, 1800710, 17145767.
34. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P, Viñals F, Tometsko M, Branstetter D, Dougall WC, González-Suárez E. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Research 2012,
35. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426. 10.1210/en.142.4.1419, 11250921.
36. Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 2011, 22:188-194. 10.1016/j.tem.2011.02.007, 21470874.
37. Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 2012, 18:326-335. 10.1158/1078-0432.CCR-10-2507, 22031096.
38. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424. 10.1101/gad.13.18.2412, 317030, 10500098.
39. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011, 121:3804-3809. 10.1172/JCI57099, 3223613, 21965337.
40. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73. 10.1016/j.cell.2009.12.007, 20074520.
41. Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 2007, 104:15852-15857. 10.1073/pnas.0706728104, 2000410, 17890319.
42. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006, 12:17-25. 10.1016/j.molmed.2005.11.007, 16356770.
43. Xu D, Wang S, Liu W, Liu J, Feng X. A Novel Receptor Activator of NF-κB (RANK) Cytoplasmic Motif Plays an Essential Role in Osteoclastogenesis by Committing Macrophages to the Osteoclast Lineage. Journal of Biological Chemistry 2006, 281:4678-4690.
44. Liu W, Xu D, Yang H, Xu H, Shi Z, Cao X, Takeshita S, Liu J, Teale M, Feng X. Functional identification of three receptor activator of nf-κb cytoplasmic motifs mediating osteoclast differentiation and function. Journal of Biological Chemistry 2004, 279:54759-54769. 10.1074/jbc.M404687200, 15485878.
45. Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 1999, 274:7724-7731. 10.1074/jbc.274.12.7724, 10075662.
46. Duheron V, Hess E, Duval M, Decossas M, Castaneda B, Klopper JE, Amoasii L, Barbaroux JB, Williams IR, Yagita H, Penninger J, Choi Y, Lezot F, Groves R, Paus R, Mueller CG. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci USA 2011, 108:5342-5347. 10.1073/pnas.1013054108, 3069202, 21402940.
47. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002, 277:44347-44356. 10.1074/jbc.M202009200, 12185073.
48. Beristain AG, Narala SR, Di Grappa MA, Khokha R. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci 2012, 125:943-955. 10.1242/jcs.094029, 22421365.